Compositions and methods for assessing the risk of cancer occurrence

A method for evaluating the risk of occurrence of a cancer in a subject who has not been previously diagnosed with cancer, the method comprising the steps of:

• a) measuring the level of progastrin in a sample of the subject, comprising the steps of:
• contacting the sample with a first anti-progastrin antibody which binds to a first part of progastrin, wherein the first anti-progastrin antibody is a monoclonal antibody produced by the hybridoma deposited at the CNCM, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris CEDEX 15, France, on 27 Dec. 2016, under reference I-5158, and contacting the sample with a second progastrin-binding antibody which binds to a second part of progastrin;
• and
• b) determining the risk that the subject will develop a cancer based on the level of step a), wherein a level of progastrin higher than 0 pM indicates that the subject has a non-negligible risk of developing a cancer.